

SAFETY DATA SHEET According to Regulation (EC) No. 1907/2006

According to Regulation (EC) No. 1907/2006 amended by Regulation (EU) No. 2020/878

Page 1 of 17

Trading name:		THROMBOGNOST S	OLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

SECTION	ON 1: Identification of	the substance	e/mixture	e and of the company/undertaking
1.1	Product identifier			
	Trading name:	THROMBO	GNOST SC	DLUTION
	Chemical name:	-		
	Catalogue number:	THR-OT-X*	*	
1.2	Relevant identified use	es of the subs	tance or m	nixture and uses advised against
	Uses:		Solution	for manual counting of thrombocytes.
	Uses advised against:		Only the	e identified uses are advised.
	Reason why uses advi	The product is intended for use only as an <i>in vitro</i> diagnomics discontinuous and the Agency for Medicinal P Medical Devices and there is no reason to use it for other		
1.3	Details of the supplier	of the safety	data shee	t
	Supplier:		BioGnost Ltd. Medjugorska 59, Zagreb +385 1 2409997 +385 1 2404039	
	Address:			
	Telephone number:			
	Telefax.:			
	e-mail of competent p	person:	msds@b	piognost.hr
	National contact:		-	
1.4	Emergency telephone	number		
	National Protection ar	nd Rescue Dire	ectorate:	112
	Medical information:			205 4 22 40 2 42
	Medical information:			+385 1 2348 342

SECTIO	ON 2. Hazards identification		
2.1	Classification of the substar	nce or mixture	
2.1.1	Classification according to I	Regulation (EC) No 1	272/2008 (CLP)
	Hazard class and ca	tegory code:	Hazard statements*:
	Carc. 1B		H350
2.1.2.	Additional information		
	-		
*For fu	ıll text of Hazard- and EU Haza	ard-statements: see S	SECTION 16
2.2	Label elements		
	Product identification:	THROMBOGNO	OST SOLUTION
	Identification number:	-	
	Authorization number:	-	



According to Regulation (EC) No. 1907/2006 amended by Regulation (EU) No. 2020/878

Page 2 of 17

Trading name:		THROMBOGNOST S	OLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

	Hazard pictograms:	GHS08			
	Signal word:	Danger			
	Hazard statements:	H350 May cause cancer.			
	Precautionary statements:	P271 Use only outdoors or in a well-ventilated area. P280 Wear protective gloves/protective clothing/eye/protection/face protection. P308+P313 IF exposed or concerned: Get medical advice/attention. P403+P233 Store in a well-ventilated place. Keep container tightly closed. P501 Dispose of contents/container according to local regulations.			
	Supplemetal hazard information (EU):	-			
2.3	Other hazards				
	Endocrine Disrupting Properties:				
	No known endocrine disrupti	No known endocrine disrupting properties			
	Results of PBT and vPvB as PBT or a vPvB.	sessment: According to the results of its assessment, this substance is not a			

SECTION 3. Co	SECTION 3. Composition/information on ingredients				
CAS/ EC/ Index number	REACH Registration No	Weight % content (or range)	Identification name	Classification according to Regulation (EC) No 1272/2008 (CLP)	
50-00-0/ 200-001-8/ 605-001-00-5	01-2119488953-20- XXXX	<1%	formaldehyde, 40%	Carc. 1B; H350 Muta. 2; H341 Acute Tox. 3; H331 Acute Tox. 3; H311 Acute Tox. 3; H301 Skin Corr. 1B; H314 Skin. Sens. 1; H317	

SECTIO	SECTION 4. First aid measures				
4.1	Description of first aid measures				
	General notes:	If the suggested first aid measures do not prove sufficient, seek medical attention.			



Page 3 of 17

Trading name:		THROMBOGNOST S	OLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

4.3	Indication of any immediate medi	cal attention and special treatment needed			
	Following ingestion:	Depending on concentration and exposure time, it may lead to stinging and digestive mucus damage, abdominal pain, nausea, vomiting.			
	Following eye contact:	Depending on concentration and exposure time, it may lead to irritation, tearing, redness and pain.			
	Following skin contact:	Depending on concentration and exposure time, it may lead to irritation, rash, skin drying and skin cracking.			
	Following inhalation:	Depending on concentration and exposure time, it may lead to mucosa irritation, cough, and dyspnea.			
4.2	Most important symptoms and eff	Most important symptoms and effects, both acute and delayed			
	Self-protection of the first aider:	-			
	Following ingestion:	Rinse the oral cavity, drink at most 1-2 glasses of water. Do not induce vomiting. Immediately consult a physician and show the container or label. In case of swallowing large quantities, transport the afflicted person to the hospital.			
	Following eye contact:	Rinse out with plenty of water with the eyelid held wide open for at least 20 minutes. If the symptoms remain, immediately call in ophthalmologist.			
	Following skin contact:	Remove contaminated clothing. Immediately wash with plenty of water for at least 20 minutes. Seek medical assistance if the symptoms of irritation remain.			
	Following inhalation:	Carry the afflicted person out of the contaminated area into a well-ventilated area or out for fresh air. In case of respiratory arrest, provide artificial respiration (while not exposing the provider). In case of unconsciousness, transport the afflicted person in the lateral position. Seeking medical advice is advised.			

SECTIO	SECTION 5. Firefighting measures			
5.1	Extinguishing media			
	Suitable extinguishing media:	Water spray, dry powder, CO ₂ or alcohol resistant foam.		
	Unsuitable extinguishing media:	No information available		
5.2	Special hazards arising from the substance or mixture			
	Hazardous combustion products:	Formalin solution is not flammable in itself. Gases released from the solution are flammable if the concentration of the solution is >25%. In case of combustion carbon dioxide and carbon monoxide will be released, which are heavier than air. Vapours are heavier than air and may spread along the floors. Forms explosive mixtures with air on intense heating. Development of hazardous combustion gases or vapours possible in the event of fire.		



Page 4 of 17

Trading name:		THROMBOGNOST S	OLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

5.3	Advice for firefighters
	Use a self-contained open-circuit compressed air breathing apparatus and fireproof clothing.
5.4	Additional information
	Remove sources of heat and ignition. Do not contaminate the environment with extinguishing media.

6.1	Personal precautions, protective	ve equipment and emergency procedures	
6.1.1.	For non-emergency personnel		
	Protective equipment:	Use personal protective equipment (see Section 8).	
	Accident prevention methods:	Evacuate members of all non-essential personnel and those members without protective equipment. Avoid breathing vapors and avoid contact with skin and eyes. Do not smoke.	
	Emergency procedures:	Mark the area using proper signs.	
6.1.2.	For emergency responders:		
	Use protective equipment; in a (see Section 8).	case of inadequate ventilation use adequate airways protective equipment	
6.2	Environmental precautions:		
	Do not dispose of in sewage, or Protection and Rescue Directo	drainage system and waterways. In case of large spillage contact National rate (NPRD) on 112.	
6.3	Methods and material for conf	tainment and cleaning up	
6.3.1.	Bunding, covering of drains; capping procedures:	Sand or clay barriers.	
6.3.2.	Cleaning up:	Where possible, the substance can be absorbed by using absorbing material. Place the waste material in tightly closed impermeable containers. Store the substance in well ventilated storage rooms until disposal. Submit for disposal to the legal persons authorized by the Ministry of Environmental and Nature Protection. After disposal of the products, wash the area and involved materials with water.	
6.3.3.	Other information:	Do not use incompatible materials (see Section 10).	
6.4	Reference to other sections		
	See Section 7 for information	on safe handling.	
	See Section 8 for information	on personal protection equipment.	
	See Section 13 for disposal inf	ormation.	

SECTIO	SECTION 7. Handling and storage		
7.1	Precautions for safe handling		
7.1.1.	Protection measures		
	Measures to prevent fire:	Use in well ventilated storage rooms. Keep away from sources of ignition and heat.	



Page 5 of 17

Trading name:	THROMBOGNOST SOLUTION					
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4	

	Measures to prevent aerosol and dust generation	on:	Secure proper ventilation.		
	Measures to protect the environment:		Prevent spilling into the sewage system and waterways.		
	Other measures:		-		
7.1.2.	Advice on general occupational hygiene:				
	Do not eat, drink or smoke in the workspace. The	noroughly was	h hands after work and before eating.		
7.2	Conditions for safe storage, including any incompatibilities				
	Technical measures and storage conditions:		htly closed and upright set containers at res ranging from +15 to +25 °C.		
	Packaging materials:	Manufactu containers	Manufacturer's original packaging. Avoid metal ontainers. eep away from food and drink. Keep the containers ghtly closed.		
	Requirements for storage rooms and vessels:				
	Advices for storage equipment:	must be re	e must be made of hard material; floors sistant to chemicals. There must be no drain ly leads into sewage system. Secure proper		
	Further information on storage conditions:	and do no	ce the unused material in the storage room t use empty containers for storing other Do not store with incompatible materials n 10).		
7.3	Specific end use(s)	·			
	Recommendations:	-			
	Industrial sector specific solutions:	-			

SECTION 8. Expos	SECTION 8. Exposure controls/personal protection							
8.1 Control parameters								
Substance	Substance		CAS No		Occupational exposure limit values/short term values		Biologic	al limit values
				ppm	1	mg/m³		
Formaldehyde		50-00-0		2		2.5		-
Substance name:	-							
EC No:	-	CAS No	: -					
DNEL								
	Industrial							
Route of	Acu	ite	Acu	te		Chronic		Chronic
exposure:	effect	local	effect sy	stemic		effect local	ef	fect systemic



Page 6 of 17

Trading	name:	TI			ROMBOGNOST SOLUTION				
Product	code:	THR-OT-X**		Date o	of compilation: 03 April		03 April 2	2023	Version: 4
			ı						
Oral		-	-			-		-	
Inhalation	1	0.75 mg/m ³ (formaldehyde)	-			0.375 mg/m ³ (formaldehyde))	9 mg/m³ (f	ormaldehyde)
Dermal		-	-		0.037 mg/cm ² (formaldehyde)		240 mg/kg	(formaldehyde)	
Critical ph	Critical physical parameters: solubility, flammability			oility, cor	ros	ivity: -			
				Co	nsu	ımer			
Route of exposure		Acute effect local		cute systemic	С	Chroni effect lo	-		Chronic ct systemic
Oral		-	-			-		4.1 mg/kg	(formaldehyde)
Inhalation	1	-	-			0.1 mg/m³ (formaldehyde))	3.2 mg/m ³	(formaldehyde)
Dermal		-	-			0.012 mg/cm ² (formaldehyde))	102 mg/kg	(formaldehyde)
PNEC									
Environm	ental prot	ection target			PNEC				
Fresh wat	er				0.44 mg/l (formaldehyde)				
Freshwate	er sedime	nts			2.3 mg/kg (formaldehyde)				
Marine w	ater				0.44 mg/l (formaldehyde)				
Marine se	diments				2.3 mg/kg (formaldehyde)				
Food cha	in				No information available				
Microorg	anisms in	sewage treatment			0.19 mg/l (formaldehyde)				
Soil (agric	cultural)				0.2	2 mg/kg (formal	dehyde)		
Air					No	o information av	ailable		
8.2	Exposi	ure controls							
8.2.1.	Appro	priate engineering	controls						
		ance/mixture related measures to nt exposure during identified uses:			Use the product in well ventilated rooms. Use personal protective equipment. Do not eat, drink or smoke in the workspace.			•	
	Structi exposi	tural measures to prevent sure:			In accordance with Section 7.				
	_	ganisational measures to prevent posure:		nt	Organization of work in order to reduce other worker's influence during work process.			ther worker's	
	Techn	ical measures to pre	event exp	oosure:	Secure proper workspace ventilation in order to keep concentration levels in air below permitted levels.		•		
8.2.2.	Persor	nal protection equip	ment						



Page 7 of 17

Trading name:	THROMBOGNOST SOLUTION						
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4		

8.2.2.1.	Eye and face protection:	Safety glasses that stick to face (EN 166) or visor in case of lower levels of concentration in air; protective gas mask that covers the entire face in case of higher levels of concentration in air.
8.2.2.2.	Skin protection	
	Hand protection:	The protective gloves have to satisfy the specification of Regulation (EU) 2016/425 and the related standard EN374. Full contact: Glove material: nitrile rubber Glove thickness: 0.40 mm Time until perforation: > 480 min Splash contact: Gloves material: polychloroprene Glove thickness: 0.65 mm Time until perforation: > 240 min
	Other body parts protection:	Complete suit protecting against chemicals (EN 340) The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace and shoes that cover the entire foot.
8.2.2.3.	Respiratory protection:	Not required under normal conditions of use. Use suitable respiratory protective device when high concentrations are present.
8.2.2.4.	Thermal hazards:	No information available
8.2.3.	Environmental exposure controls	
	Substance/mixture related measures to prevent exposure:	See Section 6
	Structural measures to prevent exposure:	Use modern equipment.
	Organisational measures to prevent exposure:	Adapt the work process to the required working conditions of the workplace.
	Technical measures to prevent exposure:	See Section 6

SECT	SECTION 9. Physical and chemical properties				
9.1 Information on basic physical and chemical properties					
		Value	Method		
	Physical state:	liquid	Visual inspection		
	Colour:	dark blue - purple	Visual inspection		
	Odour/odour threshold:	No information available	No information available		
	Melting point / freezing point:	No information available	No information available		



Page 8 of 17

Trading name:	THROMBOGNOST SOLUTION					
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4	

	Boiling point or initial boiling point and boiling range:	No information available	No information available
	Flammability:	No information available	No information available
	Lover and upper explosion limit:	No information available	No information available
	Flash point:	No information available	No information available
	Auto-ignition temperature:	No information available	No information available
	Decomposition temperature:	No information available	No information available
	рН:	No information available	No information available
	Kinematic viscosity:	No information available	No information available
	Solubility:	No information available	No information available
	Partition coefficient n- octanol/water (log value):	No information available	No information available
	Vapour pressure:	No information available	No information available
	Density and/or relative density	No information available	No information available
	Relative vapour density:	No information available	No information available
	Particle characteristics:	No information available	No information available
9.2	Other information		
	-		

SECTION	SECTION 10. Stability and reactivity				
10.1	Reactivity:	See subsections 10.3 through 10.5.			
10.2	Chemical stability:	The product is chemically stable under standard ambient conditions of storing and using (room temperature).			
10.3	Possibility of hazardous reactions:	No dangerous reactions known.			
10.4	Conditions to avoid:	Sources of heat, sparks, ignition, and low temperature.			
10.5	Incompatible materials:	No information available			
10.6	Hazardous decomposition products:	No information available			

SECTION 11. To	SECTION 11. Toxicological information								
11.1 Informa	11.1 Information on toxicological effects								
Acute to	oxicity:								
Route of exposure:	Method	Species Dose LD ₅₀ /LC ₅₀ or Exposure time		Results					
Oral: -		rat	LD ₅₀	No information available	100 mg/kg (formaldehyde)				
Dermal: rabbit		rabbit	LD ₅₀	No information available	300 mg/kg (formaldehyde)				



SAFETY DATA SHEET ling to Regulation (EC) No. 1907/

According to Regulation (EC) No. 1907/2006 amended by Regulation (EU) No. 2020/878

Page 9 of 17

Trading name:		THROMBOGNOST SOLUTION									
Product code:	THR-OT	-X**		Date of o	compilation	on:	03 Ap	ril 2023		Version:	4
Inhalation:	-		rat		LD ₅₀			4 h		3 mg/ (formaldel	
1											
Specific	target orga	n toxicit	y – single ex	posure (S	STOT SE):						
		Spec	ific effects			Target	organ			Note	
Oral:	No info	rmation	available		No infor	mation	availab	ole ·	-		
Dermal:	No info	rmation	available		No infor	mation	availab	ole ·	_		
Inhalation:	No info	rmation	available		No infor	mation	availab	ole ·	-		
Aspiratio	on hazard:			No infor	mation av	ailable.					
Irritation	and corros	ion									
		Exposur	e time	Spec	ies	Evalua	tion	Method		Note	
Skin	_			_	_	_	-	_	_		
corrosion/irritation	on:										
Serious eye damage/irritation	-			-	-	-	-	-	-		
Ė											
Sensitiza	ation	1									
Skin sensitization	•	-									
Respiratory sensi	tization:	-									
Sympton	ms related t	o the pl	nysical, chem	nical and t	toxicologi	cal char	acterist	ics			
Oral exposure:		_	on concentra ige, nausea,		-	time, it	may lea	ad to sting	ing an	d digestive	
Dermal exposure	•	Depending on concentration and exposure time, redness accompanied by sensation stinging and pain may occur, as well as skin cracking and rash.							sensation o	f	
Inhalation exposu	re. Depe	Depending on concentration and exposure time, it may lead to mucosa irritation, and dyspnea.							tation, coug	ıh,	
Eye exposure:			n concentra	tion and	exposure :	time it	may lea	ad to stina	ina te	aring and r	nain
гус схрозите.	Бере	inding c	on concentra	tion and	схрозите	tirrie, re	Thay ice	ad to string	ing, te	aring, and p	, diri.
Reneate	d dose tovi	rity (sub	acute, subch	oronic ch	ronic)						
Керейс	u dosc toxi	city (3uc	Exposure	irorne, err	ionic)						
	Dose	e	time	Speci	es	Metho	od	Evaluati	on	Note	
Subacute oral	No infor	mation	No informatio available	No n inforr availa	mation able	No inform availal		No informa availabl		-	



Page 10 of 17

Trading name:		THROMBOGNOST S	OLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

Subacute dermal	No availa	information able	No information available	No information available	No information available	No information available	on	-
Subacute inhalation	No availa	information able	No information available	No information available	No information available	No information available	on	-
Subchronic oral	No availa	information able	No information available	No information available	No information available	No information available		-
Subchronic dermal	No availa	information able	No information available	No information available	No information available	No information available	on	-
Subchronic inhalation	No availa	information able	No information available	No information available	No information available	No information available	on	-
Chronic oral	No availa	information able	No information available	No information available	No information available	No information available		-
Chronic dermal	No availa	information able	No information available	No information available	No information available	No information available		-
		ahle I I I I I I I I I I I I I I I I I I I						
Chronic inhalation	No availa		information	information	information	No information available	on	-
inhalation	availa	able	information available	information available	information available	information	on	-
inhalation	availa	able	information available y – repeated e	information available xposure (STOT	information available RE):	informatio available	on	
inhalation Specific	availa	organ toxicit	information available y – repeated e Specific effec	information available xposure (STOT	information available RE):	information available available		Note
Specific Subacute oral	availa target	organ toxicit	information available y – repeated e Specific effect ation available	information available xposure (STOT	information available RE): Target o	information available available available available available	- -	
Specific Subacute oral Subacute derma	availa target	organ toxicit No informa No informa	information available y – repeated e Specific effec- ation available ation available	information available xposure (STOT	information available RE): Target o No information	information available rgan available n available	_	
Specific Subacute oral Subacute derma Subacute inhala	availa target	organ toxicit No informa No informa No informa	information available y – repeated e Specific effect ation available	information available xposure (STOT	information available RE): Target o	information available available available available available available available	_	
inhalation	availa target	organ toxicit No informa No informa No informa No informa	information available y – repeated e Specific effec- ation available ation available	information available xposure (STOT	information available RE): Target of the No information of the N	information available in availa	_	
Subacute oral Subacute derma Subacute inhalar Subchronic oral Subchronic dern	availa target	organ toxicit No informa No informa No informa No informa No informa	information available y – repeated e Specific effection available ation available ation available	information available xposure (STOT	information available RE): Target of the No information No infor	information available in availa	_	
Specifical Subacute oral Subacute inhalation Subchronic oral Subchronic dern Subchronic inha	availa target	organ toxicit No informa No informa No informa No informa No informa No informa	information available y – repeated e Specific effect ation available ation available ation available ation available ation available	information available xposure (STOT	information available RE): Target of the No information	information available in availa	_	
Specific Subacute oral Subacute derma Subacute inhalar Subchronic oral	availa target	organ toxicit No informa No informa No informa No informa No informa No informa No informa	information available y – repeated e Specific effect ation available ation available ation available ation available ation available ation available	information available xposure (STOT	information available RE): Target of the No information	information available in availa	_	



Page 11 of 17

Trading name:	THROMBOGNOST SOLUTION						
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4		

	Mutagenicity in vitro:	No information available.
	Genotoxicity:	No information available.
	Mutagenicity in vivo:	No information available.
	Germ cell mutagenicity:	No information available.
	Reproductive toxicity:	No information available.
	Summary of evaluation of the CMR properties:	No information available.
11.2.	Information on other hazards:	
11.2.1.	Endocrine disrupting properties:	
	No known endocrine disrupting properties that affect human health.	
11.2.2.	Other informations:	
	-	

SECTION 12. Ecologic	cal informat	ion				
12.1 Toxicity						
Acute (short-term) toxicity	Dose	Exposure time	Species	Method	Evaluation	Note
Fish	LC ₅₀	96 hours	Pimephales promelas	-	6.7 mg/l (formaldehyde)	-
Crustacea:	EC ₅₀	48 hours	Daphnia magna	-	5.8 mg/l (formaldehyde)	-
Algae/aquatic plants	IC ₅₀	4 days	algae	-	4.89 mg/l (formaldehyde)	-
Other organisms	-	-	-	-	-	-
Chronic (long-term) toxicity	Dose	Exposure time	Species	Method	Evaluation	Note
Fish	LC ₅₀	96 hours	No information available	No informatio n available	No information available	-
Crustacea:	EC ₅₀	48 hours	No information available	No informatio n available	No information available	-
Algae/aquatic plants	IC ₅₀	72 hours	No information available	No informatio n available	No information available	-



Page 12 of 17

Tradin	g name:			THROMBOGNOST SOLUTION							
Produc	ct code:		THR-OT-X**		Da	ite of compila	ation:	03 April 202	3	Version:	4
								1			
Other c	organisms	5	-	-	-		-	-		-	
12.2	Persiste	ence	and degrada	bility							
	Abiotic	deg	gradation								
		[Degradation l	nalf-lives	Method			Evaluation	Note		
Marine	water	No	information	available	No ii avail	nformation able	No ir availa	nformation able	-		
Fresh w	<i>r</i> ater	No	information	available	No ii avail	nformation able	nation No information available		-		
Air		No	information	available	No ii avail	nformation able	No ir availa	nformation able	-		
Soil		No	information	available	No ii avail	nformation able		No information available			
	Biodeg	rada	ation				3				
% De	egradatio	n	Time	(days)		Method	Evaluation		Note		
	rmation		No information					No information available		rmation	
availabl	le		available		avaıl	able	avaliable		availab	le	
12.3	Pioacci	ımıı	lative potenti	al							
12.5			ater partition		log Ko	,,,,)					
Valu			centration	pH	°C	Method		Evaluation		Note	
- vaiu	-	COII	Centration		<u> </u>	-		- Evaluation	_	Note	
	Biocono	cent	ration factor	(BCF)							
V	/alue		Spec			Method		Evaluation		Note	
	rmation			nformation				information ilable	-		
avallabl			avanable		availe		ava				
	Chronic	eco	otoxicity								
	Carrottic		Concies								



According to Regulation (EC) No. 1907/2006 amended by Regulation (EU) No. 2020/878

Page 13 of 17

Trading name:		THROMBOGNOST	SOLUTION	<u> </u>	
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

Value	Dose	Exposure time	Species	Method	Evaluation	Note
Chronic toxicity on fish	LC ₅₀	No information available	No information available	No informati on available	No information available	-
Chronic toxicity on crustacea (<i>Daphnia</i>)	EC ₅₀	No information available	No information available	No informati on available	No information available	-
12.4 Mobility in soil						
Known or predic	ted distributi	on in environm	nental compart	ments:		

12.7	Wiobility III 30	/11			
	Known or pre	edicted distributi	on in environmental	compartments:	
	No information	on available			
	Surface tension	on:			
	Value	°C	Concentration	Method	Note
	No information available	No information available	No information available	No information available	-

Adsorption / desorption

Transport	A/D coefficient Henry's constant		log Kow	Evaporation rate	Method	Note
Soil-water	No available	information	No information available	No information available	No information available	-
Water-air	No available	information	No information available	No information available	No information available	-
Soil-air	No available	information	No information available	No information available	No information available	-

12.5. Results of PBT and vPvB assessment

No information available

12.6. Endocrine disrupting properties

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.



SAFETY DATA SHEET ling to Regulation (FC) No. 1907/

According to Regulation (EC) No. 1907/2006 amended by Regulation (EU) No. 2020/878

Page 14 of 17

Trading name:		THROMBOGNOST	SOLUTION	
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version: 4

12.7.	Other adverse effects	
	No information available	
SECTION	N 13. Disposal considerations	
13.1	Waste treatment methods	
13.1.1.	Product/Packaging disposal:	
		sed of according to the national and local rules and regulations. Do not Submit for disposal to the legal person authorized by the Ministry of tection.
13.1.2.	Waste codes/waste designation	
	15 01 10*: packaging that cont substances	ains residual hazardous substances or is contaminated with hazardous
13.1.3.	Waste treatment – relevant info	ormation:
	No information available	
13.1.4.	Sewage disposal – relevant info	ormation:
	Waste must not be disposed or	f into the sewage system.
13.1.5.	Other disposal recommendation	ons:
	authorized by the ministry in cl	's remains into the sewage system. Submit the remains to the collectors harge. Do not dispose of the packaging into the sewage system. Submit authorized by the ministry in charge.
13.1.6.	Relevant Community provision	s:
	Directive 2009/98/EC on waste	and repealing certain directives.
SECTION	N 14 TRANSPORT INFORMATIO	ON CONTRACTOR OF THE PROPERTY
	Transporting/shipment by road (ADR)
UN number:		Not subject to transport regulations
UN proper shipping name:		-
Transpo	rt hazard class(es):	-
Packing	group:	-
Environr	nentally hazardous:	-
Special p	precautions for user:	-



According to Regulation (EC) No. 1907/2006 amended by Regulation (EU) No. 2020/878

Page 15 of 17

Trading name:	THROMBOGNOST SOLUTION		SOLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

UN number:	Not subject to transport regulations
UN proper shipping name:	-
Transport hazard class(es):	-
Packing group:	-
Environmentally hazardous:	-
Special precautions for user:	-
Inland waterway transport (ADN)	
UN number:	Not subject to transport regulations
UN proper shipping name:	-
Transport hazard class(es):	-
Packing group:	-
Environmentally hazardous:	-
Special precautions for user:	-
Transporting/shipment by sea (II	MDG)
UN number:	Not subject to transport regulations
UN proper shipping name:	-
Transport hazard class(es):	-
Packing group:	-
Environmentally hazardous:	-
Special precautions for user:	-
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC code:	-
Transporting/shipment by air (IC	AO-TI/IATA-DGR)
UN number:	3334
UN proper shipping name:	Aviation regulated liquid, n.o.s. (formaldehyde)
Transport hazard class(es):	9
Packing group:	III
Environmentally hazardous:	None
Special precautions for user:	No information

SECTION 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture



SAFETY DATA SHEET According to Regulation (EC) No. 1907/2006

amended by Regulation (EU) No. 2020/878

Page 16 of 17

Trading name:	THROMBOGNOST		SOLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

	EU regulations	
	Authorization and/or restri	ctions of use
	Authorizations:	-
	Restrictions:	-
	Other EU regulations:	Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC; Directive 2004/42/CE of the European Parliament and of the Council of 21 April 2004 on the limitation of emissions of volatile organic compounds due to the use of organic solvents in certain paints and varnishes and vehicle refinishing products and amending Directive 1999/13/EC; Council Directive 98/24/EC of 7 April 1998 on the protection of the health and safety of workers from the risks related to chemical agents at work; Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006; REACH Restrictions on the manufacturing, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII);
	Information according 1999 guideline)	9/13/EC about limitation of emissions of volatile organic compounds (VOC-
	National legislation:	Chemicals Act, Regulation on classification, packaging and labeling of dangerous substances, Ordinance on occupational exposure limit values and on biological limit values, Regulation on categories, types and classification of waste with a waste catalog and list of hazardous waste, Ordinance on writing Material safety data sheet, Transport of Hazardous Substances Act
15.2	Chemical safety assessmen	t
	None	

SECTION 16. Other information	
16.1 Indication of changes:	-



According to Regulation (EC) No. 1907/2006 amended by Regulation (EU) No. 2020/878

Page 17 of 17

Trading name:	THROMBOGNOST		SOLUTION		
Product code:	THR-OT-X**	Date of compilation:	03 April 2023	Version:	4

16.2	Abl	previations and acronyms:	ADR: Accord relatif au transport international des marchandises dangereuses par route (European Agreement Concerning the International Carriage of Dangerous Goods by Road) IMDG: International Maritime Code for Dangerous Goods IATA: International Air Transport Association GHS: Globally Harmonised System of Classification and Labelling of Chemicals EINECS: European Inventory of Existing Commercial Chemical Substances CAS: Chemical Abstracts Service (division of the American Chemical Society) DNEL: Derived No-Effect Level (UK REACH) LC50: Lethal concentration, 50 percent LD50: Lethal dose, 50 percent PBT: Persistent, Bioaccumulative and Toxic vPvB: very Persistent and very Bioaccumulative
16.3.	Key literature references and source of data:		-
16.4.	Classification and procedure 1272/2008 (CLP)		used to derive the classification for mixture according to Regulation (EC)
Classifi	Classification		Classification procedure
_	-		-
16.5.	Relevant H statements (num		per and full text)
		301+311+331	Toxic if swallowed, in contact with skin or if inhaled.
		314	Causes severe skin burns and eye damage
	H:	317	May cause allergic skin reaction.
		341	Suspected of causing genetic defects.
		350	May cause cancer.
16.6.	i.6. Training advice: -		-
			** "X" in the product code marks different volumes (different packagings of the product)
16.7.			We are not responsible for consequences in case of failure to comply with instructions for use or improper use of the product described in this material safety data sheet.

ANNEX: Exposure scenario resulting to chemical safety assessment